Overview

By reviewing case presentations, Lee Schwartzberg, MD, and Sally Yowell Barbour, PharmD, discuss best practices in classifying patients at risk for chemotherapy-induced nausea and vomiting (CINV), minimizing CINV risk in patients, and collaborating with other health care professionals on preventive and management strategies.

Watch video case presentations by the Faculty.

Proceed at your own pace and in any order.

Compare your knowledge against your peers' knowledge.

Download slides to your library.

Content Areas

  • Patient- and chemotherapy regimen-associated risk factors for CINV
  • Classification of CINV
  • Agents available for treatment of CINV
  • Guideline-recommended strategies

This activity was developed for oncologists, hematologists/oncologists, oncology pharmacists, and other health care professionals who care for patients at risk for chemotherapy-induced nausea and vomiting.


This activity is supported by independent educational grants from Merck Sharp & Dohme Corp, Helsinn Therapeutics, Inc, and Eisai Inc.

Faculty

Lee S. Schwartzberg, MD, FACP

Lee S. Schwartzberg, MD, FACP

Executive Director, West Cancer Center
Professor of Medicine and Chief, Division of Hematology/Oncology
University of Tennessee Health Science Center
Memphis, Tennessee

Sally Yowell Barbour, PharmD, BCOP, CPP

Sally Yowell Barbour, PharmD, BCOP, CPP

Clinical Oncology Pharmacist
Director of Oncology Pharmacy Programs
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Enter your information to begin.
Activity Resources
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
1.00 ACPE Contact Hour
Course Opens: October 26, 2016
Course Expires: October 25, 2017
Target Audience Oncologists
Hematologist/Oncologists
Oncology Pharmacists
Other Health Care Providers